The use (or rather the non-use) of cost-effectiveness data in priority setting decisions - are we underestimating the barriers to using health economics in real world priority setting decisions?

被引：1
|
作者：
Erntoft, Sandra T. [1 ]
机构：
[1] LEO Pharma AS, Copenhagen, Denmark
来源：
INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT | 2015年 / 4卷 / 03期
关键词：
Health Policy; Cost-effectiveness; Priority Setting;
D O I：
10.15171/ijhpm.2015.28
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
After having practicing and researching health economics for nearly 15 years now, it has become clear to me that the use of cost-effectiveness data in priority setting decisions is rather a rare than a common practice. The Eckard et al. article though, describes a wonderful exception to this rule and a very good example of how it can be used when the conditions are right. However, do we fully understand what these conditions are? In this commentary article I will address some of the institutional and cultural conditions that need to be fulfilled in order for cost-effectiveness data to actually be used in priority setting decisions.
引用
收藏
页码：181 / 183
页数：3
相关论文
共 9 条
  • [1] Use of cost-effectiveness data in priority setting decisions: experiences from the national guidelines for heart diseases in Sweden
    Eckard, Nathalie
    Janzon, Magnus
    Levin, Lars-Ahe
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2014, 3 (06): : 323 - 332
  • [2] Priority Setting for Universal Health Coverage: We Need to Focus Both on Substance and on Process Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, not Just More Evidence on Cost-Effectiveness"
    Lauer, Jeremy A.
    Rajan, Dheepa
    Bertram, Melanie Y.
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2017, 6 (10): : 601 - 603
  • [3] Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness
    Baltussen, Rob
    Jansen, Maarten P.
    Mikkelsen, Evelinn
    Tromp, Noor
    Hontelez, Jan
    Bijlmakers, Leon
    Van der Wilt, Gert Jan
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2016, 5 (11) : 615 - 618
  • [4] Don't Discount Societal Value in Cost-Effectiveness Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness"
    Hall, William
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2017, 6 (09) : 543 - 545
  • [5] Cost-effectiveness of second-line therapies in real-world setting: an economic evaluation of the EDGE study using patient level data
    McEwan, P.
    Evans, M.
    Foos, V.
    Paldanius, P. M.
    [J]. DIABETOLOGIA, 2015, 58 : S482 - S482
  • [6] Health Technology Assessment: Global Advocacy and Local Realities Comment on "Priority Setting for Universal Health Coverage: We Need Evidence-Informed Deliberative Processes, Not Just More Evidence on Cost-Effectiveness"
    Chalkidou, Kalipso
    Li, Ryan
    Culyer, Anthony J.
    Glassman, Amanda
    Hofman, Karen J.
    Teerawattananon, Yot
    [J]. INTERNATIONAL JOURNAL OF HEALTH POLICY AND MANAGEMENT, 2017, 6 (04) : 233 - 236
  • [7] COMPARISON OF THE LONG-TERM COST-EFFECTIVENESS OF IDEGLIRA VERSUS MULTIPLE DAILY INSULIN INJECTIONS IN THE SPANISH SETTING USING REAL-WORLD CLINICAL DATA
    Mezquita, P.
    Basse, A.
    Thorsted, B. L.
    Pollock, R. F.
    Price, H.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A479 - A479
  • [8] USE OF REAL-WORLD BIG DATA TO ASSESS THE EFFECTIVENESS ON OVERALL SURVIVAL AMONG CHEMOTHERAPY OR IMMUNOTHERAPY IN FIRST LINE METASTATIC NON-SMALL CELL LUNG CARCINOMA PATIENTS IN AN ITALIAN SETTING
    Degli Esposti, L.
    Sangiorgi, D.
    Ancona, D. D.
    Andretta, M.
    Barbieri, A.
    Bartolini, F.
    Cavaliere, A.
    Chinellato, A.
    Ciaccia, A.
    Cillo, M. R.
    Citraro, R.
    Costantini, A.
    De Francesco, A.
    Dell'Orco, S.
    Di Manno, G.
    Ferrante, F.
    Gentile, S.
    Lavalle, A.
    Moscogiuri, R.
    Pastorello, M.
    Procacci, C.
    Re, D.
    Santoleri, F.
    Ubertazzo, L.
    Vercellone, A.
    Perrone, V
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S3 - S3
  • [9] Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.
    Sabater, Javier
    Ralph, Lewis
    Batteson, Rachael
    McCarthy, Grant
    Wex, Jaro
    Vera, Shanti Ricardo Moreno
    Becquart, Martin
    Mounedji, Nadjat
    Taieb, Julien
    Peeters, Marc
    Falcone, Alfredo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
1